Caribou Biosciences, Inc. (CRBU)

Market Cap	129.49M
Revenue (ttm)	11.48M
Net Income (ttm)	-148.12M
Shares Out	90.55M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,659,185
Open	1.380
Previous Close	1.310
Day's Range	1.320 - 1.570
52-Week Range	1.320 - 8.330
Beta	2.34
Analysts	Strong Buy
Price Target	11.80 (+725.18%)
Earnings Date	Mar 10, 2025

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBU
• Website: https://cariboubio.com

Financial Performance

In 2023, Caribou Biosciences's revenue was $34.48 million, an increase of 148.91% compared to the previous year's $13.85 million. Losses were -$102.07 million, 2.66% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $11.8, which is an increase of 725.18% from the latest price.

Price Target

$11.8

(725.18% upside)

Analyst Consensus: Strong Buy